 high-dos cytarabin daunorubicin induct postremiss chemotherapi treatment acut myelogen leukemia adult seventi consecut adult patient acut myelogen leukemia aml median age year high-dos cytarabin hour dose daunorubicin dose remiss induct singl ident cours postremiss therapi complet remiss CR patient confid interv CI singl cours patient elect bone marrow transplant bmt first CR patient underw post-cr therapi patient earli relaps excess toxic induct chemotherapi refus nineteen patient plan post-cr therapi continu CR median follow-up year year actuari leukemia-fre surviv Cl patient CR Cl patient post-cr chemotherapi analysi variou put prognost factor CR overal leukemia-fre surviv signific previou histori myelodysplasia initi leukocyt count certain french-american-british fab type certain abnorm karyotyp none factor signific paramet small patient number certain analys signific associ myelosuppress remiss induct post-cr therapi sever cerebellar toxic patient case toxic revers other seriou complic infrequ intens chemotherapi high-dos cytarabin daunorubicin substanti antileukem activ adult aml improv convent therapi relaps common patient plan therapi substanti toxic optimum use regimen aml